|  |
| --- |
| The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program.The PBAC agenda consists of the following:**1 Minutes of Previous Meeting****2 Chair’s report (verbal)****3 Matters arising from the minutes** **4 Matters arising/outstanding****5 New drug applications****6 Requests for changes to listings****7 Resubmissions****8 Pricing Matters****9 Matters relating to PBS review****10 Subcommittee and Working Party reports****11 Other business****12 Correspondence****13 Further information****14 Late papers****15 Tabled papers**Consumers will have the opportunity to provide comments on new drug submissions (item 5), changes to listings (item 6) and resubmissions (item 7). In many circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceutical benefits listed in the Schedule fall into three broad categories:*Unrestricted benefits* – have no restrictions on their therapeutic uses; *Restricted benefits* – can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and *Authority required benefits* – Authority required benefits fall into two categories: * *Authority required benefits* require prior approval from Services Australia or the DVA (noted as Authority required)
* *Authority required (STREAMLINED) benefits* do not require prior approval from Services Australia or the DVA but require the recording of a streamlined authority code (noted as Authority required (STREAMLINED)).

Initial submissions are categorised broadly as:* *Category 1 or 2:* Submissions to list new medicines on the Schedule of Pharmaceutical Benefits or to make substantial changes to current listings are generally classified as Category 1 or 2 submissions. These submissions require presentation of an economic evaluation.
* *Category 3 or 4:* Submissions that relate to new forms of previously listed products and changes to the conditions of use e.g. change in maximum quantity/repeats or clarifying the wording of a restriction (while not altering the intended use) are considered to be Category 3 or 4 submissions. These submissions do not usually require the presentation of an economic evaluation.

Resubmissions are categorised broadly as Standard Re-entry Pathway, Early Resolution Pathway, Early Re-entry Pathway or Facilitated Resolution Pathway. Submission categories and resubmission pathways are outlined in the [Procedure Guidance](https://www.pbs.gov.au/info/industry/listing/listing-steps). The PBAC meeting agenda will be published in week 3 – and updated in week 8 (to include early pathway resubmissions, and items for review under the process for reviewing positive PBS-listing recommendations not accepted by applicants) in each PBAC cycle as per [PBS Calendar](https://www.pbs.gov.au/info/industry/useful-resources/pbs-calendar).  |

| **Drug Name, form(s), strength(s) and Sponsor, Submission type**(Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing) | **Drug Type and Use**(What is the drug used to treat?) | **Listing requested by Sponsor / Purpose of Submission**(Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| --- | --- | --- |
| ACCESS TO MEDICINES FOR PEOPLE IN CUSTODIAL SETTINGSVARIOUS MEDICINESDEPARTMENT OF HEALTH AND AGED CARE(Other matters) | Various medicines | The Department seeks to update the PBAC with advice received from the States and Territories concerning access to medicines for people in custodial settings and to seek further PBAC advice. |
| ADALIMUMABInjection 20 mg in 0.2 mL pre-filled syringeInjection 40 mg in 0.4 mL pre-filled syringeInjection 40 mg in 0.4 mL pre-filled penInjection 80 mg 0.8 mL pre-filled syringeInjection 80 mg in 0.8 mL pre-filled penHumira®ABBVIE PTY LTD(Change to existing listing) | Vision threatening non-infectious uveitis | Resubmission to request a General Schedule Authority Required (Telephone/Online) listing for the treatment of patients with vision-threatening non-infectious uveitis. |
| ADALIMUMABInjection 20 mg in 0.2 mL pre-filled syringeInjection 40 mg in 0.4 mL pre-filled syringeInjection 40 mg in 0.4 mL pre-filled penInjection 80 mg in 0.8 mL pre-filled syringeInjection 80 mg in 0.8 mL pre-filled penHumira®ABBVIE PTY LTD(Change to existing listing) | Immune-mediated inflammatory disease | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of immune-mediated inflammatory disease in paediatric patients.  |
| ADALIMUMABInjection 80 mg in 0.8 mL pre-filled penInjection 80 mg in 0.8 mL pre-filled syringeYuflyma®CELLTRION HEALTHCARE AUSTRALIA PTY LTD(New PBS listing) | Complex refractory fistulising Crohn diseaseUlcerative colitisCrohn diseaseChronic plaque psoriasisHidradenitis suppurativa | To request General Schedule Authority Required (Written) listing of Yuflyma® 80 mg for initial and first continuing treatment, and Authority Required (STREAMLINED) listing for subsequent continuing treatment under the same conditions as its reference biologic Humira®.  |
| AFLIBERCEPTSolution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL)Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL) pre-filled syringeEylea®BAYER AUSTRALIA LTD(New PBS listing)TO BE CONSIDERED AT A FUTURE PBAC MEETING | Diabetic macular oedema (DMO) | To request a General Schedule Authority Required (Written) listing for the treatment of patients with visual impairment due to DMO. |
| AFLIBERCEPTSolution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL)Solution for intravitreal injection 11.34 mg in 100 microlitres (114.3 mg per mL) pre-filled syringe Eylea®BAYER AUSTRALIA LTD(New PBS listing)TO BE CONSIDERED AT A FUTURE PBAC MEETING | Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration | To request a General Schedule Authority Required (Written) listing for the treatment of visual impairment caused by CNV secondary to age-related macular degeneration. |
| AMINO ACID FORMULA SUPPLEMENTED WITH PREBIOTICS, PROBIOTICS AND LONG CHAIN POLYUNSATURATED FATTY ACIDSOral powder 400 g (Neocate Syneo)Neocate® SyneoNUTRICIA AUSTRALIA PTY LIMITED(Other matters) | Cows' milk protein enteropathySevere cows' milk protein enteropathy with failure to thriveCombined intolerance to cows' milk protein, soy protein and protein hydrolysate formulaeProven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy proteinCows' milk anaphylaxis Severe intestinal malabsorption including short bowel syndromeEosinophilic oesophagitis | To request Neocate® Syneo with new formulation continue to be listed on the PBS under the existing conditions. |
| AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT PHENYLALANINEOral liquid 125 mL, 30 (PKU Lophlex Select LQ)PKU Lophlex® Select LQNUTRICIA AUSTRALIA PTY LIMITED(New PBS listing) | Phenylketonuria (PKU) | To request a General Schedule Restricted Benefit listing for the dietary management of PKU.  |
| AMINO ACID FORMULA WITH VITAMINS, MINERALS AND LONG CHAIN POLYUNSATURATED FATTY ACIDS WITHOUT PHENYLALANINEOral powder 400 g (PKU Start)PKU Start™VITAFLO AUSTRALIA PTY LIMITED(Other matters) | Phenylketonuria (PKU) | To request PKU Start with new formulation continue to be listed on the PBS under the existing conditions. |
| ANIFROLUMABSolution concentrate for I.V. infusion 300 mg in 2 mLSaphnelo®ASTRAZENECA PTY LTD(New PBS listing) | Systemic lupus erythematosus (SLE) | Resubmission to request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of severe SLE with a high level of disease activity despite standard therapy. |
| ATEZOLIZUMABSolution for subcutaneous injection containing atezolizumab 1875 mg in 15 mLTecentriq® SCROCHE PRODUCTS PTY LTD(New PBS listing) | Locally advanced or metastatic non-small cell lung cancer (NSCLC)Stage IV (metastatic) NSCLCExtensive-stage small cell lung cancerAdvanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinomaResected early stage (Stage II to IIIA) NSCLC | To request listing of a new form and strength of atezolizumab under the same conditions as the currently listed form and strengths of atezolizumab solution for intravenous (I.V.) infusion.  |
| AVACOPANCapsule 10 mgTavneos®SEQIRUS (AUSTRALIA) PTY LTD(New PBS listing) | Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) | Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for treatment of severe active granulomatosis with polyangiitis (GPA) and severe active microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphamide. |
| BECLOMETASONE WITH FORMOTEROL Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 doseFostair®CHIESI AUSTRALIA PTY LTD(Change to existing listing) | Asthma | To request a General Schedule Authority Required (STREAMLINED) listing as a maintenance and reliever treatment for asthma.  |
| BEVACIZUMABSolution for I.V. infusion 100 mg in 4 mLSolution for I.V. infusion 400 mg in 16 mLVegzelma®CELLTRION HEALTHCARE AUSTRALIA PTY LTD(New PBS listing) | Cancers | To request a Section 100 (Efficient Funding of Chemotherapy) Unrestricted Benefit listing of Vegzelma® under the same conditions as the PBS-listed bevacizumab biosimilars. |
| BIMEKIZUMABInjection 160 mg in 1 mL single use pre-filled syringeInjection 160 mg in 1 mL single use pre-filled penBimzelx®UCB AUSTRALIA PROPRIETARY LIMITED(New PBS listing) | Psoriatic arthritis (PsA) | To request a General Schedule Authority Required (Written) listing for the treatment of PsA. |
| BIMEKIZUMABInjection 160 mg in 1 mL single use pre-filled syringeInjection 160 mg in 1 mL single use pre-filled penBimzelx®UCB AUSTRALIA PROPRIETARY LIMITED(New PBS listing) | Ankylosing spondylitis (AS) | To request a General Schedule Authority Required (Written) listing for the treatment of AS. |
| BIMEKIZUMABInjection 160 mg in 1 mL single use pre-filled syringeInjection 160 mg in 1 mL single use pre-filled penBimzelx®UCB AUSTRALIA PROPRIETARY LIMITED(New PBS listing) | Non-radiographic axial spondyloarthritis (nr-axSpA) | To request a General Schedule Authority Required (Written) listing for the treatment of nr-axSpA. |
| BRENTUXIMAB VEDOTINPowder for I.V. infusion 50 mgAdcetris®TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.(Change to existing listing) | Hodgkin lymphoma | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Telephone/Online) listing for the first-line treatment of advanced classical Hodgkin lymphoma. |
| BUDESONIDE Capsule (enteric) 3 mgBudenofalk®DR FALK PHARMA AUSTRALIA PTY LTD(New PBS listing) | Crohn disease (CD) | To request a General Schedule Authority Required (STREAMLINED) listing of a new form of budesonide for the treatment of mild to moderate CD.  |
| BULEVIRTIDEPowder for injection 2 mgHepcludex®GILEAD SCIENCES PTY LIMITED(New PBS listing) | Chronic hepatitis D | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listing for the treatment of chronic hepatitis D.  |
| CABOZANTINIBTablet 20 mgTablet 40 mgCabometyx®IPSEN PTY LTD(Change to existing listing) | Renal cell carcinoma (RCC) | To request a General Schedule Authority Required (STREAMLINED) listing, in combination with nivolumab, for the first-line treatment of advanced clear cell RCC. |
| CABOZANTINIBTablet 20 mgTablet 40 mgTablet 60 mgCabometyx®IPSEN PTY LTD(Change to existing listing) | Renal cell carcinoma (RCC) | To request an amendment to the existing General Schedule Authority Required (STREAMLINED) listing to remove the ‘clear cell variant’ histology requirement to allow treatment in patients with non-clear cell RCC. |
| CABOZANTINIBTablet 20 mgTablet 40 mgTablet 60 mgCabometyx®IPSEN PTY LTD(Change to existing listing) | Differentiated thyroid cancer (DTC) | Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for the treatment of locally advanced or metastatic DTC in patients who have progressed during or after prior vascular endothelial growth factor-targeted therapy. |
| CETUXIMABSolution for I.V. infusion 100 mg in 20 mLSolution for I.V. infusion 500 mg in 100 mLErbitux®MERCK HEALTHCARE PTY LTD(Change to existing listing) | Metastatic colorectal cancer (mCRC) | To request an increase of maximum amount for the existing listings of cetuximab to allow clinician choice of either weekly or fortnightly dosing regimen for the treatment of mCRC.  |
| DABRAFENIBCapsule 50 mg (as mesilate)Capsule 75 mg (as mesilate)Tablet (dispersible) 10 mgTafinlar® TRAMETINIBTablet 500 microgramsTablet 2 mgPowder for oral solution 5 micrograms per mL (as dimethylsulfoxide), 97 mLMekinist® NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED(Change to existing listing) | Glioma | To request a General Schedule Authority Required (Telephone/Online) listing for the treatment of paediatric patients with BRAF V600E mutation positive low grade glioma or high grade glioma, and to request new forms and strengths of dabrafenib and trametinib. |
| DAPAGLIFLOZIN WITH SITAGLIPTINTablet containing dapagliflozin 10 mg with sitagliptin 100 mg Sidapvia®ASTRAZENECA PTY LTD(New PBS listing) | Type 2 diabetes mellitus (T2DM) | To request a General Schedule Authority Required (STREAMLINED) listing, for use in combination with metformin, for the treatment of T2DM. |
| DAUNORUBICIN WITH CYTARABINEPowder for I.V infusion containing daunorubicin 44 mg and cytarabine 100 mgVyxeos®JAZZ PHARMACEUTICALS ANZ PTY LTD(New PBS listing)WITHDRAWN | Acute myeloid leukaemia | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Telephone/Online) listing for the treatment of therapy-related acute myeloid leukaemia (t-AML) or acute myeloid leukaemia with myelodysplasia-related changes (AML-MRC) while system and IT challenges relating to aSection 100 (Efficient Funding of Chemotherapy) listing are resolved.  |
| DUPILUMAB Injection 200 mg in 1.14 mL single dose pre-filled syringeInjection 300 mg in 2 mL single dose pre-filled syringeDupixent®SANOFI-AVENTIS AUSTRALIA PTY LTD(Change to existing listing) | Asthma | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of uncontrolled severe asthma in patients aged 6 to 11 years. |
| EDARAVONESolution concentrate for injection I.V. infusion 30 mg in 20 mLRadicava®TEVA PHARMA AUSTRALIA PTY LTD(New PBS listing) | Amyotrophic lateral sclerosis (ALS) | Resubmission to request a Section 100 (Highly Specialised Drugs Program) Authority Required (Telephone/Online) listing for the treatment of ALS. |
| ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTORPack containing 56 sachets containing granules elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor 75 mg and 28 sachets containing granules ivacaftor 75 mgPack containing 56 sachets containing graunules elexacaftor 80 mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets containing granules ivacaftor 59.5 mgTrikafta®VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD.(New PBS listing) | Cystic fibrosis  | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of cystic fibrosis in patients who are aged 2 to 5 years and who have at least one F508del mutation on the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene. |
| EMPAGLIFLOZINTablet 10 mgJardiance®BOEHRINGER INGELHEIM PTY LTD(Change to existing listing) | Chronic heart failure | To request a change in the General Schedule Authority Required (STREAMLINED) listing for the treatment of chronic heart failure to allow treatment initiation by nurse practitioners. |
| ETRASIMODTablet 2 mgVelsipity®PFIZER AUSTRALIA PTY LTD(New PBS listing) | Ulcerative colitis | To request a General Schedule Authority Required (Written) listing for the treatment of moderate to severe ulcerative colitis. |
| EVOLOCUMABInjection 140 mg in 1 mL single use pre-filled penInjection 420 mg in 3.5 mL single use pre-filled cartridgeRepatha®AMGEN AUSTRALIA PTY LIMITED(Change to existing listing) | Hypercholesterolaemia | To request a change to the restriction level of the existing listings for initial treatment from Authority Required (Telephone/Online) to Authority Required (STREAMLINED). The submission also requested a change in the clinical criteria to reduce the minimum treatment duration required with both a statin and ezetimibe prior to initiating evolocumab. |
| GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINEOral liquid 250 mL, 18 (PKU GMPro ULTRA LQ)PKU GMPro® ULTRA LQNUTRICIA AUSTRALIA PTY LIMITED(New PBS listing)WITHDRAWN | Phenylketonuria (PKU) | To request a General Schedule Restricted Benefit listing for the dietary management of PKU in patients who are aged 3 years and over. |
| IBRUTINIBCapsule 140 mgTablet 280 mgTablet 420 mgImbruvica®JANSSEN-CILAG PTY LTD(New PBS listing) | Chronic lymphocytic leukaemia (CLL) or Small lymphocytic lymphoma (SLL) | Resubmission to request a General Schedule Authority Required (Telephone/Online) listing, for use in combination with venetoclax, for the treatment of previously untreated CLL or SLL. |
| ICOSAPENT ETHYLCapsule 1 gVazkepa®SEQIRUS (AUSTRALIA) PTY LTD(New PBS listing) | Atherosclerotic cardiovascular disease with elevated triglycerides | Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for the treatment of atherosclerotic cardiovascular disease with elevated triglycerides. |
| INFLUENZA VACCINE Injection (0.5 mL)Flucelvax® QuadSEQIRUS (AUSTRALIA) PTY LTD(Change to existing listing) | Prevention of influenza  | To request a National Immunisation Program listing for the prevention of influenza in patients aged 6 months and older. |
| INFLUENZA VACCINEInjection (0.5 mL)Flublok® QuadrivalentSANOFI-AVENTIS AUSTRALIA PTY LTD(New NIP listing) | Prevention of influenza | To request a National Immunisation Program listing for the prevention of influenza in patients aged 65 years and over. |
| IRINOTECANSolution for I.V. infusion containing nanoliposomal irinotecan (as sucrosofate) 43 mg in 10 mLOnivyde®SERVIER LABORATORIES (AUST.) PTY. LTD.(New PBS listing) | Pancreatic cancer | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing, for use in combination with oxaliplatin, 5-fluorouracil and folinic acid/leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma. |
| LAROTRECTINIBCapsule 25 mg (as sulfate)Capsule 100 mg (as sulfate)Oral solution 20 mg per mL (as sulfate), 50 mL, 2Vitrakvi®BAYER AUSTRALIA LTD(Change to existing listing) | Non-small cell lung cancer (NSCLC) or soft tissue sarcoma (STS) harbouring neurotrophic receptor tyrosine kinase (*NTRK*) gene fusions | Resubmission to request a General Schedule Authority Required (Written) listing for the treatment of locally advanced or metastatic NSCLC or STS harbouring *NTRK* gene fusions.  |
| LEBRIKIZUMAB Injection 250 mg in 2 mL single use autoinjectorEbglyss®ELI LILLY AUSTRALIA PTY LTD(New PBS listing) | Atopic dermatitis | To request a General Schedule Authority Required (Telephone/Online) listing for the treatment of severe atopic dermatitis. |
| LEVODOPA WITH CARBIDOPA AND ENTACAPONEIntestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg and with entacapone 20 mg per mL, 47 mLLecigon®STADA PHARMACEUTICALS AUSTRALIA PTY LIMITED(New PBS listing) | Parkinson disease  | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of advanced idiopathic Parkinson disease with severe motor fluctuations despite optimised alternative pharmacological treatment. |
| MEPOLIZUMABPowder for injection 100 mgInjection 100 mg in 1 mL single dose pre-filled penNucala®GLAXOSMITHKLINE AUSTRALIA PTY LTD(Change to existing listing) | Uncontrolled severe asthma | To request a change to the restriction level of the existing listings for initial treatment from Authority Required (Written) to Authority Required (Telephone/Online), and for continuing treatment from Authority Required (Written) to Authority Required (STREAMLINED) for the treatment of uncontrolled severe asthma. The submission also requested a change to the current requirement for treating with oral corticosteroids as part of optimised asthma therapy for the initial treatment of uncontrolled severe asthma.  |
| MIGALASTATCapsule containing migalastat hydrochloride 150 mgGalafold®AMICUS THERAPEUTICS PTY LTD(New PBS listing) | Fabry disease | To request the PBAC consider its previous recommendation to list migalastat as a General Schedule Authority Required (Written) listing for the treatment of Fabry disease, and to request an amendment to the restriction criteria to be consistent with international clinical guidelines for Fabry disease.  |
| NIVOLUMABInjection concentrate for I.V. infusion 100 mg in 10 mLInjection concentrate for I.V. infusion 40 mg in 4 mLOpdivo®BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD(Change to existing listing) | Non-small cell lung cancer (NSCLC)  | To extend the Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of neoadjuvant treatment of resectable NSCLC to allow retreatment. |
| NIVOLUMABInjection concentrate for I.V. infusion 100 mg in 10 mLInjection concentrate for I.V. infusion 40 mg in 4 mLOpdivo®BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD(Change to existing listing) | Muscle invasive urothelialcarcinoma (MIUC) | To request reconsideration for a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Telephone/Online) listing for the adjuvant treatment of high-risk MIUC. This matter was deferred at the November 2023 PBAC meeting. |
| OFATUMUMABSolution for injection 20 mg in 0.4 mL pre-filled penKesimpta®NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED(Change to existing listing) | Multiple sclerosis | To request separating the current higher efficacy disease modifying therapies (DMT) tier into two distinct efficacy tiers.  |
| OSILODROSTATTablet 1 mgTablet 5 mgIsturisa®RECORDATI RARE DISEASES AUSTRALIA PTY. LTD.(New PBS listing) | Cushing syndrome | Resubmission to request the General Schedule Authority Required (Telephone/Online) listing for the treatment of endogenous Cushing syndrome. |
| PEGCETACOPLANSolution for intravitreal injection 15 mg in 0.1 mL (150 mg per mL)Syfovre®APELLIS AUSTRALIA PTY LTD(New PBS listing)WITHDRAWN | Geographic atrophy secondary to age related macular disease | To request a General Schedule Authority Required (Written) listing for the treatment of non-subfoveal geographic atrophy that is secondary to age-related macular degeneration.  |
| PRASUGRELTablet 5 mgTablet 10 mgPrasugrel SCPGENERIC HEALTH PTY LTD(New PBS listing) | Acute coronary syndrome  | To request a General Schedule Authority Required (STREAMLINED) listing, in combination with aspirin, for the treatment of acute coronary syndrome (myocardial infarction or unstable angina) managed by percutaneous coronary intervention. |
| RAVULIZUMABSolution concentrate for I.V. infusion 300 mg in 3 mLSolution concentrate for I.V. infusion 1,100 mg in 11 mLUltomiris®ALEXION PHARMACEUTICALS AUSTRALASIA PTY LTD(New PBS listing)TO BE CONSIDERED AT A FUTURE PBAC MEETING | Generalised myasthenia gravis (gMG)  | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of adult patients with gMG who are anti-acetylcholine receptor antibody positive. |
| RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATETablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mgRyeqo®GEDEON RICHTER AUSTRALIA PTY LTD(New PBS listing) | Endometriosis | To request a General Schedule Authority Required (STREAMLINED) listing for the treatment of moderate to severe pain associated with endometriosis. |
| RESPIRATORY SYNCYTIAL VIRUS VACCINEInjection (0.5 mL)Abrysvo®PFIZER AUSTRALIA PTY LTD(New NIP listing) | Prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) | To request National Immunisation Program listing for the prevention of lower respiratory tract illness caused by RSV in infants from birth through to 6 months of age by active immunisation of pregnant individuals. |
| RIMEGEPANTTablet (orally disintegrating) 75 mgNurtec® ODTPFIZER AUSTRALIA PTY LTD(New PBS listing) | Acute migraine attacks | Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for adults with migraine who have not responded adequately to treatment of at least two triptans. |
| RISPERIDONEI.M. injection (modified release), set containing 1 pre-filled syringe powder for injection 75 mg and 1 pre-filled syringe diluent 383 microlitresI.M. injection (modified release), set containing 1 pre-filled syringe powder for injection 100 mg and 1 pre-filled syringe diluent 490 microlitres Okedi®MAXX PHARMA PTY LTD(New PBS listing) | Schizophrenia | To request a General Schedule AuthorityRequired (STREAMLINED) listing for thetreatment of schizophrenia. |
| ROMOSOZUMABInjection 105 mg in 1.17 mL single use pre-filled syringeEvenity®AMGEN AUSTRALIA PTY LIMITED(Change to existing listing) | Osteoporosis | To request the PBAC consider its previous recommendation to list romosozumab as a General Schedule Authority Required(Telephone/Online) listing for the treatment of severe osteoporosis in the first-line setting. |
| SELUMETINIB Capsule 10 mgCapsule 25 mgKoselugo®ALEXION PHARMACEUTICALS AUSTRALASIA PTY LTD(New PBS listing) | Neurofibromatosis type 1 (NF1) | Resubmission to request a General Schedule Authority Required (Written) listing for the treatment of symptomatic, inoperable plexiform neurofibroma(s) in paediatric patients aged 2 years and over with NF1. |
| SIPONIMODTablet 1 mg (as hemifumarate)Mayzent®NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED(New PBS listing) | Multiple sclerosis | To request a General Schedule Authority Required (STREAMLINED) listing of a new strength of siponimod for the treatment of relapsing-remitting multiple sclerosis. |
| SODIUM ZIRCONIUM CYCLOSILICATESachet containing powder for oral suspension (as hydrate) 5 gSachet containing powder for oral suspension (as hydrate) 10 gLokelma®ASTRAZENECA PTY LTD(New PBS listing) | Chronic hyperkalaemia  | To request a General Schedule Authority Required (Telephone/Online) listing for the treatment of chronic hyperkalaemia in patients with chronic kidney disease Stage 3-4. |
| TADALAFILTablet 20 mgTadalisCIPLA AUSTRALIA PTY LTD(New PBS listing) | Pulmonary arterial hypertension (PAH) | To request listing of a new pack size for tadalafil 20 mg of 60 tablets under the same conditions as the existing listings of the 56-pack size for the treatment of PAH. |
| TALAZOPARIBCapsule 0.1 mg Capsule 0.25 mgCapsule 0.35 mgCapsule 0.5 mg Talzenna®PFIZER AUSTRALIA PTY LTD(New PBS listing) | Prostate cancer (PC) | To request a General Schedule Authority Required (STREAMLINED) listing, in combination with enzalutamide, for the treatment of metastatic castration resistant PC in patients with a Breast Cancer Gene 1 (*BRCA1*) or *BRCA2* mutation who have not received prior treatment with a novel hormonal agent. |
| TIOTROPIUMCapsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) Tiotropium LupinGENERIC HEALTH PTY LTD(New PBS listing) | Chronic obstructive pulmonary disease (COPD) | To request a General Schedule Restricted Benefit listing ofa new form of tiotropium for the treatment of COPD. |
| TOFACITINIBTablet (modified release) 11 mg Xeljanz® XRPFIZER AUSTRALIA PTY LTD(New PBS listing) | Rheumatoid arthritis (RA)Psoriatic arthritis (PsA)  | To request listing of a new form and strength for tofacitinib under the same conditions as the existing listings of tofacitinib 5 mg for the treatment of severe active RA and severe PsA. |
| TRASTUZUMAB DERUXTECANPowder for I.V. infusion 100 mgEnhertu®ASTRAZENECA PTY LTD(New PBS listing) | Human epidermal growth factor receptor 2 (HER2)-low breast cancer | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Telephone/Online) listing for the treatment of patients with HER2-low unresectable or metastatic breast cancer. |
| USTEKINUMABInjection 45 mg in 0.5 mL single use pre-filled syringeInjection 45 mg in 0.5 mL single use pre-filled penInjection 90 mg in 1 mL single use pre-filled syringeInjection 90 mg in 1 mL single use pre-filled penStelara®JANSSEN-CILAG PTY LTD(New PBS listing) | Psoriatic arthritis (PsA) Crohn disease (CD)Chronic plaque psoriasis (CPP)Ulcerative colitis (UC)Fistulising Crohn disease | To request Authority Required (Written) listing of new forms, and amendments to the current restrictions for severe CD and severe CPP to align with a change in the quantity required for adult patients resulting from the new listings. |
| USTEKINUMABInjection 45 mg in 0.5 mLInjection 45 mg in 0.5 mL single use pre-filled syringeInjection 90 mg in 1 mL single use pre-filled syringeSolution for I.V. infusion 130 mg in 26 mLWezlana®AMGEN AUSTRALIA PTY LIMITED(New PBS listing) | Psoriatic arthritisCrohn diseaseChronic plaque psoriasisUlcerative colitis | To request General Schedule and Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listings of ustekinumab biosimilar under the same conditions as its reference biologic. |
| VEDOLIZUMABInjection 108 mg in 0.68 mL single use pre-filled penPowder for injection 300 mgEntyvio®TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD.(Change to existing listing) | Crohn diseaseUlcerative colitis | To request a change to the clinical criteria to allow an additional dose of vedolizumab 300 mg at Week 10 for the initial treatment of severe Crohn disease. The submission also requested the removal of the requirement to assess the risk of developing progressive multifocal leukoencephalopathy during this treatment from all PBS listings for vedolizumab. |
| VENETOCLAXPack containing 14 tablets venetoclax 10 mg and 7 tablets venetoclax 50 mg and 7 tablets venetoclax 100 mg and 14 tablets venetoclax 100 mgTablet 10 mgTablet 50 mgTablet 100 mgVenclexta®ABBVIE PTY LTD(Other matters)WITHDRAWN | Chronic lymphocytic leukaemia (CLL) | To request consideration of the current treatment duration and the eligible population being treated with venetoclax in the treatment of CLL.  |
| BECLOMETASONE WITH FORMOTEROLPressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doseFostair®Chiesi Australia Pty Ltd(Review of positive PBAC recommendations not accepted by applicants) | Chronic obstructive pulmonary disease (COPD) | - |
| BIMEKIZUMABSolution for injection 160 mg in 1 mL pre-filled penSolution for injection 160 mg in 1 mL pre-filled syringeBimzelx®UCB Australia Proprietary Limited(Review of positive PBAC recommendations not accepted by applicants) | Plaque psoriasis | - |
| DUPILUMAB Injection 200 mg in 1.14 mL single dose pre-filled syringeInjection 300 mg in 2 mL single dose pre-filled syringeDupixent®Sanofi-Aventis Australia Pty Ltd(Review of positive PBAC recommendations not accepted by applicants) | Atopic dermatitis in children 6 to 11 years of age | - |
| ENOXAPARINInjection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringeInjection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL syringeInjection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL syringeInjection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringeInjection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringeInjection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringeInjection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL syringeEnoxapo®Apotex Pty Ltd(Review of positive PBAC recommendations not accepted by applicants) | Antithrombotic | - |
| FREMANEZUMAB Solution for injection 225 mg in 1.5 mL single dose pre-filled syringeAjovy®Teva Pharma Australia Pty Ltd(Review of positive PBAC recommendations not accepted by applicants) | Treatment-resistant migraine (change to maximum quantity and number of repeats) | - |
| GALCANEZUMAB Injection 120 mg in 1 mL pre-filled penEmgality®Eli Lilly Australia Pty Ltd(Review of positive PBAC recommendations not accepted by applicants) | Treatment-resistant high frequency episodic migraine | - |
| GLYCOMACROPEPTIDE FORMULA WITH AMINO ACIDS, CARBOHYDRATES, MINERALS AND LOW PHENYLALANINESachets containing oral powder 12.5 g, 30 (PKU GMPro Mix-In)PKU GMPro Mix-In®Nutricia Australia Pty Limited(Review of positive PBAC recommendations not accepted by applicants) | Phenylketonuria | - |
| GLYCOMACROPEPTIDE FORMULA WITH AMINO ACIDS, VITAMINS, MINERALS, TRACE ELEMENTS, CARBOHYDRATE, FAT AND LOW PHENYLALANINESachets containing oral powder 33.4 g, 30 (PKU GMPro ULTRA)PKU GMPro ULTRA®Nutricia Australia Pty Limited(Review of positive PBAC recommendations not accepted by applicants) | Phenylketonuria | - |
| OZANIMOD Capsule 920 microgramsPack containing 4 capsules 230 micrograms and 3 capsules 460 microgramsZeposia®Celgene Pty Limited(Review of positive PBAC recommendations not accepted by applicants) | Ulcerative colitis | - |
| RABEPRAZOLE Tablet containing rabeprazole sodium 20 mg (enteric coated)Pariet®Janssen-Cilag Pty Ltd(Review of positive PBAC recommendations not accepted by applicants) | Gastro-oesophageal reflux disease | - |
| RISANKIZUMAB Injection 150 mg in 1 mL pre-filled syringeInjection 150 mg in 1 mL pre-filled penSkyrizi®AbbVie Pty Ltd(Review of positive PBAC recommendations not accepted by applicants) | Psoriatic arthritis | - |
| SECUKINUMABSolution for injection 300 mg in 2 mL pre-filled penSolution for injection 300 mg in 2 mL pre-filled syringeCosentyx®Novartis Pharmaceuticals Australia Pty Limited(Review of positive PBAC recommendations not accepted by applicants) | New strength forNon-radiographic axial spondyloarthritisSevere active psoriatic arthritisSevere psoriatic arthritisAnkylosing spondylitisActive ankylosing spondylitisSevere chronic plaque psoriasis | - |
| SOMAPACITAN Injection 10 mg in 1.5 mL pre-filled penSogroya®Novo Nordisk Pharmaceuticals Pty. Limited(Review of positive PBAC recommendations not accepted by applicants) | Adult-onset growth hormone deficiency | - |
| DUPILUMABInjection 200 mg in 1.14 mL single dose pre-filled syringeInjection 300 mg in 2 mL single dose pre-filled syringeDupixent®SANOFI-AVENTIS AUSTRALIA PTY LTD(Sub-committee reportDUSC Analysis) | Severe asthma | To assess the utilisation of dupilumab for the treatment of uncontrolled severe asthma.  |
| NIVOLUMABInjection concentrate for I.V. infusion 100 mg in 10 mLInjection concentrate for I.V. infusion 40 mg in 4 mL Opdivo® IPILIMUMABInjection concentrate for I.V. infusion 200 mg in 40 mLInjection concentrate for I.V. infusion 50 mg in 10 mL Yervoy® BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD(Sub-committee reportDUSC Analysis) | Mesothelioma | To assess the utilisation of nivolumab and ipilimumab for the treatment of unresectable malignant mesothelioma.  |
| PROGESTERONE All brands and strengths Various sponsors (Sub-committee reportDUSC Analysis) | Prevention of preterm birth | To assess the utilisation of progesterone for the prevention of preterm birth.  |
| ROMOSOZUMAB Injection 105 mg in 1.17 mL single use pre-filled syringeEvenity®AMGEN AUSTRALIA PTY LIMITED (Sub-committee reportDUSC Analysis) | Osteoporosis | To assess the utilisation of romosozumab for the treatment of severe established osteoporosis. |
| OPIOID DEPENDENCE TREATMENT MEDICINES ACCESSBUPRENORPHINEBuvidal® WeeklyBuvidal® Monthly CAMURUS PTY LYDSubutex®Sublocade®INDIVIOR PTY LTDBUPRENORPHINE WITH NALOXONESuboxone® Film 2/0.5Suboxone® Film 8/2INDIVIOR PTY LTDMETHADONEAspen Methadone SyrupASPEN PHARMACARE AUSTRALIA PTY LIMITEDBiodone® ForteBIOMED AUST PTY LIMITED(Change to existing listing) | Opioid dependence | To provide the PBAC with an update on the transition of the ODT program to the Section 100 Highly Specialised Drugs (HSD) Program (Community Access), including feedback from stakeholders on the impacts of the maximum repeats that was set for these listings.To seek the advice of the PBAC on whether it would be appropriate to amend the circumstances under which ODT medicines are listed on the PBS. |

Version 6

Items added or amended

* + - * 1. ATEZOLIZUMAB (Tecentriq® SC ) –Trade name amended
				2. BIMEKIZUMAB (Bimzelx®) – Drug type and use amended
				3. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta®) – Form amended
				4. INFLUENZA VACCINE (Flublok® Quadrivalent) – Submission type amended
				5. RESPIRATORY SYNCYTIAL VIRUS VACCINE (Abrysvo®) – Submission type amended
				6. TIOTROPIUM (Tiotropium Lupin) – Form amended

Items added or amended previously

* + - * 1. RAVULIZUMAB (Ultomiris®) – To be considered at a future PBAC meeting
				2. DAUNORUBICIN WITH CYTARABINE (Vyxeos®) – Withdrawn
				3. VENETOCLAX (Venclexta®) – Withdrawn
				4. AFLIBERCEPT (Eylea®) - To be considered at a future PBAC meeting
				5. AFLIBERCEPT (Eylea®) - To be considered at a future PBAC meeting
				6. ACCESS TO MEDICINES FOR PEOPLE IN CUSTODIAL SETTINGS (Various medicines) – Added
				7. CABOZANTINIB (Cabometyx®) – Added
				8. TRAMETINIB (Mekinist®) – Form amended
				9. EDARAVONE (Radicava®) – Added
				10. ICOSAPENT ETHYL (Vazkepa®) – Added
				11. RIMEGEPANT (Nurtec® ODT) – Added
				12. RISPERIDONE (Okedi®) – Added
				13. TIOTROPIUM (Tiotropium Lupin™) – Added
				14. TRASTUZUMAB DERUXTECAN (Enhertu®) – Added
				15. BECLOMETASONE WITH FORMOTEROL (Fostair®) - Review of positive PBAC recommendations not accepted by applicants – Added
				16. BIMEKIZUMAB (Bimzelx®) - Review of positive PBAC recommendations not accepted by applicants – Added
				17. DUPILUMAB (Dupixent®) - Review of positive PBAC recommendations not accepted by applicants – Added
				18. ENOXAPARIN (Enoxapo®) - Review of positive PBAC recommendations not accepted by applicants – Added
				19. FREMANEZUMAB (Ajovy®) - Review of positive PBAC recommendations not accepted by applicants – Added
				20. GALCANEZUMAB (Emgavity®) - Review of positive PBAC recommendations not accepted by applicants – Added
				21. GLYCOMACROPEPTIDE FORMULA WITH AMINO ACIDS, CARBOHYDRATES, MINERALS AND LOW PHENYLALANINE (PKU GMPro Mix-In®) - Review of positive PBAC recommendations not accepted by applicants – Added
				22. GLYCOMACROPEPTIDE FORMULA WITH AMINO ACIDS, VITAMINS, MINERALS, TRACE ELEMENTS, CARBOHYDRATE, FAT AND LOW PHENYLALANINE (PKU GMPro Ultra®) - Review of positive PBAC recommendations not accepted by applicants – Added
				23. OZANIMOD (Zeposia®) - Review of positive PBAC recommendations not accepted by applicants – Added
				24. RABEPRAZOLE (Pariet®) - Review of positive PBAC recommendations not accepted by applicants – Added
				25. RISANKIZUMAB (Skyrizi®) - Review of positive PBAC recommendations not accepted by applicants – Added
				26. SEKUKINUMAB (Cosentyx®) - Review of positive PBAC recommendations not accepted by applicants – Added
				27. SOMAPACITAN (Sogrova®) - Review of positive PBAC recommendations not accepted by applicants – Added
				28. ADALIMUMAB (Humira®) – Purpose of submission amended
				29. AFLIBERCEPT (Eylea®) – Form amended
				30. AFLIBERCEPT (Eylea®) – Form amended
				31. ANIFROLUMAB (Saphnelo®) – Form amended
				32. BECLOMETASONE WITH FORMOTEROL (Fostair®) – Drug, form and purpose of submission amended
				33. BRENTUXIMAB VEDOTIN (Adcetris®) – Form amended
				34. DABRAFENIB (Tafinlar®) – Form and purpose of submission amended

TRAMETINIB (Mekinist®) – Form and purpose of submission amended

* + - * 1. DAPAGLIFLOZIN WITH SITAGLIPTIN (Sidapvia®) – Form amended
				2. DUPILUMAB (Dupixent®) – Form amended
				3. ELEXACAFTOR WITH TEZACAFTOR AND WITH IVACAFTOR, AND IVACAFTOR (Trikafta®) – Drug and form amended
				4. GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINE (PKU GMPro ULTRA LQ) – Form and brand amended
				5. INFLUENZA VACCINE (Flucelvax® Quad) – Drug, form and purpose of submission amended
				6. INFLUENZA VACCINE (Flublok® Quadrivalent) – Drug and form amended
				7. IRINOTECAN (Onivyde®) – Drug and form amended
				8. LAROTRECTINIB (Vitrakvi®) – Form amended
				9. LEBRIKIZUMAB (Ebglyss®) – Form amended
				10. LEVODOPA WITH CARBIDOPA AND WITH ENTACAPONE (Lecigon®) – Form amended
				11. MIGALASTAT (Galafold®) – Purpose of submission amended
				12. OFATUMUMAB (Kesimpta®) – Form amended
				13. OSILODROSTAT (Isturisa®) – Purpose of submission amended
				14. PEGCETACOPLAN (Syfovre®) – Form amended
				15. RELUGOLIX WITH ESTRADIOL AND WITH NORETHISTERONE ACETATE (Ryeqo®) – Drug and form amended
				16. RESPIRATORY SYNCYTIAL VIRUS VACCINE (Abrysvo®) – Drug and form amended
				17. SIPONIMOD (Mayzent®) – Form amended
				18. SODIUM ZIRCONIUM CYCLOSILICATE (Lokelma®) – Form amended
				19. USTEKINUMAB (Wezlana™) – Form amended
				20. CABOZANTINIB (Cabometyx®) – Form amended
				21. DAUNORUBICIN WITH CYTARABINE (Vyxeos®) – Added
				22. EVOLOCUMAB (Repatha®) – Purpose of submission amended
				23. GLYCOMACROPEPTIDE FORMULA WITH DOCOSAHEXAENOIC ACID AND LOW PHENYLALANINE (PKU GMPro ULTRA LQ) – Withdrawn
				24. NIVOLUMAB (Opdivo®) – Added
				25. PEGCETACOPLAN (Syfovre®) – Withdrawn
				26. TOFACITINIB (Xeljanz® XR) – Form amended
				27. OPIOID DEPENDENCE TREATMENT MEDICINES ACCESS (various medicines) – Added